MA31782B1 - Antagonistes du cgrp - Google Patents

Antagonistes du cgrp

Info

Publication number
MA31782B1
MA31782B1 MA32781A MA32781A MA31782B1 MA 31782 B1 MA31782 B1 MA 31782B1 MA 32781 A MA32781 A MA 32781A MA 32781 A MA32781 A MA 32781A MA 31782 B1 MA31782 B1 MA 31782B1
Authority
MA
Morocco
Prior art keywords
salts
cgrp antagonists
hydrates
relates
diastereoisomers
Prior art date
Application number
MA32781A
Other languages
Arabic (ar)
English (en)
Inventor
Dirk Gottschling
Georg Dahmann
Henri Doods
Annekatrin Heimann
Stephan Geor Mueller
Klaus Rudolf
Gerhard Schaenzle
Dirk Stenkamp
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA31782B1 publication Critical patent/MA31782B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne de nouveaux antagonistes du cgrp de formule générale (i), dans laquelle u, v, x, y, r1, r2 et r3 sont tels que définis dans la description, leurs tautomères, leurs isomères, leurs diastéréoisomères, leurs énantiomères, leurs hydrates, leurs mélanges et leurs sels ainsi que les hydrates des sels, notamment leurs sels physiologiquement compatibles avec des acides ou des bases inorganiques ou organiques. L'invention concerne également des médicaments contenant ces composés, leur utilisation et des procédés pour leur fabrication.
MA32781A 2007-10-18 2010-04-20 Antagonistes du cgrp MA31782B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07118811 2007-10-18
PCT/EP2008/063967 WO2009050234A1 (fr) 2007-10-18 2008-10-16 Antagonistes du cgrp

Publications (1)

Publication Number Publication Date
MA31782B1 true MA31782B1 (fr) 2010-10-01

Family

ID=39047647

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32781A MA31782B1 (fr) 2007-10-18 2010-04-20 Antagonistes du cgrp

Country Status (17)

Country Link
US (1) US8450327B2 (fr)
EP (2) EP2205599B1 (fr)
JP (1) JP5366960B2 (fr)
KR (1) KR20100091972A (fr)
CN (1) CN101827845A (fr)
AU (1) AU2008313733A1 (fr)
BR (1) BRPI0817835A2 (fr)
CA (1) CA2702503A1 (fr)
CO (1) CO6270226A2 (fr)
EA (1) EA201000612A1 (fr)
EC (1) ECSP10010105A (fr)
IL (1) IL204928A0 (fr)
MA (1) MA31782B1 (fr)
MX (1) MX2010003849A (fr)
NZ (1) NZ585347A (fr)
TN (1) TN2010000173A1 (fr)
WO (1) WO2009050234A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8450327B2 (en) 2007-10-18 2013-05-28 Boehringer Ingelheim International Gmbh CGRP antagonists
EP2065381A1 (fr) * 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG Antagonistes du CGRP
CA2705405A1 (fr) * 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh Nouveaux composes
CN102791692B (zh) * 2010-03-12 2015-05-27 日本曹达株式会社 叔丁氧基羰基胺化合物的制造方法
EP3102564A4 (fr) 2014-02-05 2017-10-18 Merck Sharp & Dohme Corp. Formulation de comprimé pour composés actifs vis-à-vis du cgrp
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
EA202092442A3 (ru) 2016-06-07 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
WO2018172984A1 (fr) 2017-03-23 2018-09-27 Jacobio Pharmaceuticals Co., Ltd. Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
EP4188375A4 (fr) 2020-07-29 2024-07-24 Allergan Pharmaceuticals International Limited Traitement de migraine
AU2021409718A1 (en) 2020-12-22 2023-07-13 Allergan Pharmaceuticals International Limited Treatment of migraine
MX2024003952A (es) 2021-09-27 2024-05-27 Allergan Pharmaceuticals Int Ltd Combinación que comprende atogepant para tratar la migraña.

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010042614A (ko) 1998-04-10 2001-05-25 윌리암스 로저 에이 비트로넥틴 길항제로서 복소환식 글리실 베타-알라닌 유도체
DE19911039A1 (de) 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB2355456A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CN1474810A (zh) 2000-09-14 2004-02-11 ���鹫˾ 取代脲,神经肽yy5受体拮抗剂
US6831087B2 (en) 2001-11-09 2004-12-14 Hoffmann-La Roche Inc. Pyridine substituted isoquinoline derivatives
DK1539766T3 (en) 2002-06-05 2017-04-03 Bristol Myers Squibb Co CALCITONIN GEN-RELATED PEPTIDE RECEPTOR ANTAGONISTS
DE10250080A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2005030751A2 (fr) 2003-09-08 2005-04-07 Takeda Pharmaceutical Company Limited Inhibiteurs de dipeptidyle peptidase
DE102004018795A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018794A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004019492A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7659300B2 (en) 2004-09-08 2010-02-09 Merck Sharp & Dohme Corp. Monocyclic anilide spirolactam CGRP receptor antagonists
ATE537153T1 (de) * 2004-09-09 2011-12-15 Merck Sharp & Dohme Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors
EP1770091A1 (fr) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Antagonistes CGRP, leur procédé de préparation ansi que leur utilisation comme médicaments
JP5426878B2 (ja) 2005-05-24 2014-02-26 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ−結合カセットトランスポーターのモジュレーター
RU2008103218A (ru) 2005-06-29 2009-08-10 Палау Фарма С.А. (Es) БИЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ p38-КИНАЗЫ
DE102005050892A1 (de) * 2005-10-21 2007-04-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
BRPI0711352A2 (pt) 2006-05-09 2011-09-27 Merck & Co Inc composto, composição farmacêutica, e, métodos para o antagonismo de atividade receptora de cgrp em um mamìfero, e para, tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca , ou cefaléia vascular
WO2008070014A2 (fr) 2006-12-04 2008-06-12 Neurogen Corporation Pipéridines à substitution cétonique de biaryle
WO2009034029A2 (fr) 2007-09-07 2009-03-19 Boehringer Ingelheim International Gmbh Nouveaux composés
EP2065381A1 (fr) * 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG Antagonistes du CGRP
US8450327B2 (en) 2007-10-18 2013-05-28 Boehringer Ingelheim International Gmbh CGRP antagonists
WO2009065922A2 (fr) * 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh Nouveaux composés
EP2062889A1 (fr) * 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Composés
CA2705405A1 (fr) * 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh Nouveaux composes

Also Published As

Publication number Publication date
TN2010000173A1 (fr) 2011-11-11
CA2702503A1 (fr) 2009-04-23
JP2011500637A (ja) 2011-01-06
EP2205599B1 (fr) 2012-06-06
EP2205599A1 (fr) 2010-07-14
CN101827845A (zh) 2010-09-08
MX2010003849A (es) 2010-04-27
IL204928A0 (en) 2010-11-30
WO2009050234A1 (fr) 2009-04-23
EP2386558B1 (fr) 2014-10-01
KR20100091972A (ko) 2010-08-19
ECSP10010105A (es) 2010-06-29
EA201000612A1 (ru) 2010-10-29
AU2008313733A1 (en) 2009-04-23
CO6270226A2 (es) 2011-04-20
BRPI0817835A2 (pt) 2015-03-31
NZ585347A (en) 2011-09-30
US8450327B2 (en) 2013-05-28
US20110172218A1 (en) 2011-07-14
JP5366960B2 (ja) 2013-12-11
EP2386558A1 (fr) 2011-11-16

Similar Documents

Publication Publication Date Title
TN2010000173A1 (fr) Antagonistes de cgrp
MA30291B1 (fr) Derives de l'azolopyridin-3-one en tant qu'inhibiteurs de la lipase endotheliale
MEP45308A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
MA33238B1 (fr) Composés utilisés comme antagonistes de la bradykinine b1
MA31373B1 (fr) Composes amino-heterocycliques
EP2054411A4 (fr) Nouveaux composés, isomères de ceux-ci, ou sels acceptables sur le plan pharmaceutique de ceux-ci utilisés en tant qu'antagonistes du récepteur vanilloïde, et compositions pharmaceutiques les contenant
WO2009065919A3 (fr) Nouveaux composés
MA29652B1 (fr) 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
YU65804A (sh) Nova heterociklična jedinjenja aktivna kao inhibitori beta-laktamaze
MA30411B1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA32391B1 (fr) Activateurs de la glucokinase
MA30916B1 (fr) Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine
WO2009065920A3 (fr) Nouveaux composés
MA30932B1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa -carboxylase
WO2008030412A3 (fr) Inhibiteurs de la spiropipéridine bêta-sécrétase pour le traitement de la maladie d'alzheimer
WO2007011833A3 (fr) Inhibiteurs de spiropiperidine beta-secretase pour le traitement de la maladie d'alzheimer
MA29856B1 (fr) Derives de diacylindazole en tant qu'inhibiteurs de lipases et de phospholipases
TW200602338A (en) Selected CGRP antagonists, process for preparing them and their use as pharmaceutical compositions
MA29857B1 (fr) Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases
MA38079A1 (fr) Composés de 2-phényl-5-hétérocyclyl-tétrahydro-2h-pyran-3-amine destinés à être utilisés dans le traitement du diabète et de ses troubles associés
MA31613B1 (fr) Nouveaux composes
WO2009065922A3 (fr) Nouveaux composés
MA29858B1 (fr) Derives de carbamoylbenzotriazole en tant qu'inhibiteurs de lipases et phospholipases
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
MA30912B1 (fr) Nouveaux derives de phenylsulfamoyl-benzamide en tant qu'antagonistes de la bradykinine